help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism Vol. 64, No. 1 175-179
doi:10.1210/jcem-64-1-175
Copyright © 1987 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by YAMAMOTO, I.
Right arrow Articles by TORIZUKA, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by YAMAMOTO, I.
Right arrow Articles by TORIZUKA, K.

Circulating 1,25-Dihydroxyvitamin D Concentrations in Patients with Renal Cell Carcinoma-Associated Hypercalcemia are Rarely Suppressed

ITSUO YAMAMOTO, NOBUYASU KITAMURA, JUN AOKI, JUICHI KAWAMURA, SHIGEHARU DOKOH, RIKUSHI MORITA and KANJI TORIZUKA

Calcium Laboratory, Department of Nuclear Medicine and Radiology, Kyoto University School of Medicine Kyoto
Kyoto City Hospital Mie
the Department of Urology, Mie University School of Medicine Mie
Kawasaki Medical School Kurashiki, Japan

Address all correspondence and requests for reprints to: Itsuo Ya-mamoto, M.D., Ph.D., Calcium Laboratory, Department of Nuclear Medicine and Radiology, Kyoto University School of Medicine, Sho-goin, Sakyo, Kyoto 606 Japan.

We measured serum 1,25-dihydroxyvitamin D concentrations in 18 patients with renal cell carcinoma-associated hypercalcemia. Only 2 patients (11%) had low serum 1,25-dihydroxyvitamin D (<15 pg/ml) levels, and the mean 1,25-dihydroxyvitamin D level in the 18 patients was 44 ± 30 (±SD) pg/ml, not different from the value of 42 ± 22 pg/ml in 75 age-matched normocalcemic patients with various malignancies. Eighty-seven percent (26 of 30) of the hypercalcemic patients with extensive skeletal metastases due to other malignancies or with hematological malignancies had suppressed serum 1,25-dihydroxyvitamin D levels (<15 pg/ml). In hypercalcemic patients with other malignancies and no skeletal metastases, only 54% (21 of 39) had low serum 1,25-dihydroxyvitamin D levels. The mean serum 1,25-dihydroxyvitamin D level in the latter group was 21 ± 26 pg/ml, significantly lower than that in normocalcemic patients. In renal cell carcinoma-associated hy-percalcemia, suppression of circulating 1,25-dihydroxyvitamin D concentrations is uncommon.

Received April 14, 1986.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1987 by The Endocrine Society